在心力衰竭门诊患者中,心房动和副甲状腺激素之间的关系
Kerkutluoglu Murat1, Yucel Oguzhan2, Gunes Hakan1
1Kahramanmaras Sutcu Imam University.
Kardiologiia
|October 10, 2023
概括
在心力衰竭患者中,较高的副甲状腺激素 (PTH) 水平与心房动 (AF) 有关. 这项研究发现,PTH度独立地预测了静心性心力衰竭中的AF,这表明它可以表明AF存在.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 内部医学 内部医学
背景情况:
- 心房动 (AF) 是心力衰竭 (HF) 患者经常出现的心律失常.
- 在心力衰竭中观察到血副甲状腺激素 (PTH) 水平升高.
- 在HF中PTH和AF之间的关联仍然不清楚.
研究的目的:
- 为了研究血PTH度和心衰竭患者中AF的存在之间的关系.
主要方法:
- 对131名心力衰竭患者进行前性观察性研究.
- 患者被分为两组:那些有AF (n=36) 和那些在鼻节律 (SR,n=95) 的患者.
- 统计分析包括单变量和多变量逻辑回归.
主要成果:
- 与SR患者相比,AF患者的血PTH度显著更高 (p=0.007).
- 统一分析确定了PTH,肌素清除率,血红蛋白,肌素,年龄和左心室喷射率与AF相关.
- 多变量分析显示PTH度是AF的唯一独立预测因子.
结论:
- 血PTH度与静心性心力衰竭患者的AF独立相关.
- 升高的PTH水平可以作为这个人群中AF存在的指标.
相关概念视频
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Hormones and Bone Tissue
2.7K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
2.7K
Heart Failure Drugs: Diuretics
400
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
400
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
441
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
441


